Note that some links may require subscriptions.
This year’s JP Morgan Healthcare Conference is kicking off with a deal: embattled Celgene is buying Impact Biomedicines for $1.1 billion upfront for its myelofibrosis drug fedratinib, a highly selective JAK2 kinase inhibitor. The price could reach as high as $7 billion over time if the drug reaches certain milestones. (Bloomberg)
There’s money in addiction and Google is mining lots of it, according to an investigation in The Sunday Times (via STAT)
Not to worry: Over the weekend President Trump sought to settle current questions about his mental health by going on the record with statements and tweets boasting of his mental stability and extraordinary intelligence. (CNN.com)
Pfizer says it is pulling the plug on its quests to find new drugs for Alzheimer’s and Parkinson’s, with 300 positions to be cut from its neuroscience pipeline operations in Massachusetts and Connecticut. (Reuters)
Medical student Jamie Katuna says the stress of medical school can often lead to brief emotional breakdowns, and that’s OK, especially if students are given permission to acknowledge those episodes. (KevinMD)
Business leaders in Indiana are teaming up with health professionals to lobby for repealing the state’s “smokers’ bill of rights” that prevents employers from screening applicants for tobacco use. (Indiana Business Journal)
Analysis of data from a registry of more than 180,000 Swedish heart attack patients found that women were three times more likely to die within 12 months than were men. The reason? Men get better care. (BBC)
Half of the general hospitals in two states — Connecticut and Delaware — were fined by Medicare for safety violations. Overall, 751 hospitals nationwide paid penalties under the 2017 Hospital Acquired Conditions Reduction program. (Kaiser Health News)
Danny Hakum takes a deep dive into Humira pricing and reports the secret formula: set a high baseline price and keep moving it up. (The New York Times)
Toby Cosgrove, MD, who stepped down from his 13-year reign as Cleveland Clinic CEO on December 31, told Cleveland.com that he will be continuing in an advisory role at the clinic. The new CEO, Tomislav “Tom” Mihaljevic, MD, took the reins on Jan. 1.
Morning Break is a daily guide to what’s new and interesting on the Web for healthcare professionals, powered by the MedPage Today community. Got a tip? Send it to us: MPT_editorial@everydayhealthinc.com.